Drugs / HSCT donor leukemia-specific cytotoxic T-cells
HSCT donor leukemia-specific cytotoxic T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06865352 | Feb 2021 → Jan 2025 | acute lymphoblastic leukemia, acute myeloid leukemia | Fondazione IRCCS Policlinico San Matteo di Pavia | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSCT donor leukemia-specific cytotoxic T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06865352 ↗ |
| Known as | anti-leukemia CTLs | “The Leuk-001 trial explores the safety of infusion of escalating doses of anti-leukemia CTLs in a cohort of high-risk relapse pediatric patients given haploidentical HCT for...” PMID 40547030 ↗ Jun 2025 |
| Known as | donor-derived anti-leukemia cytotoxic T lymphocytes | “Leuk-CTL-001 (EudraCT n. 2019-003362-41) is a Phase I/II clinical trial on the safety and preliminary efficacy of donor-derived anti-leukemia cytotoxic T lymphocytes (CTLs) for...” PMID 40547030 ↗ Jun 2025 |
| Action | Deplete | “exert leukemia-specific killing” NCT06865352 ↗ |
| Modality | Cell therapy | “Adoptive cell therapy based on the infusion of donor-derived CTLs” PMID 40547030 ↗ Jun 2025 |